Antimicrobial peptides and proteins (APPs) are becoming increasingly important in targeting
multidrug-resistant (MDR) bacteria. APPs is a rapidly emerging area with novel molecules …

The emerging resistance of Gram-negative bacteria is a growing problem worldwide.
Together with the financial cost, limited efficacy, and local unavailability of newer antibiotics …

Colistin is the last-resort antibiotic to treat multidrug-resistant (MDR) Gram-negative bacterial
infections that are untreatable by other clinically available antibiotics. However, the recently …

Colistin and other polymyxin antibiotics have become increasingly used in clinical settings
as a result of treating multidrug-resistant infections in critically ill patients. The highly variable …

Nebulized antibiotic therapy directly targets airways and lung parenchyma resulting in high
local concentrations and potentially lower systemic toxicities. Experimental and clinical …

A rapid, simple, and robust LC–MS/MS method was developed and validated for the
quantitation of colistin and colistin methanesulfonate (CMS) in human plasma. The method …

Colistin methanesulfonate (CMS) is the less-toxic prodrug of highly nephrotoxic colistin. To
develop and understand highly necessary new antibiotic formulations, the hydrolysis of CMS …

Asumir la noción de intertexto desde criterios asentados, hizo que los estudios recientes
conformaran las características de aquella noción a partir de las interrelaciones entre …

Colistin is a multicomponent polypeptide antibiotic consisting mainly of colistin A and colistin
B, produced by selected strains of Bacillus polymyxa var. Colistinus. Only recently, the …

Colistin and carbapenems, vital last-resort antibiotics against severe bacterial infections
unresponsive to common drugs, pose a significant threat when resistance develops …